Company Profile

Personalised Therapies For The Heart And Vasculature Innovativeindependentclose To The Patientwe Are A Biotech Company That Independently Develops Innovative Drugs And Diagnostics For Personalised Treatment Of Cardiovascular Diseaseswe Have A Unique Product Pipeline That We Are Consistently Moving Into Clinical Trialsour Lead Compound Has Been Successfully Tested In Two Phase Ii Studies We Work Closely Together With Excellent Academic And Clinical Teams In Basic And Clinical Researchwe Use State Of The Art Analytical Methodsand We Develop Our Products According To The Highest Quality Standardsglpgmp And Gcp Revacept Is A Therapeutic Agent For The Prevention And Treatment Of Acute Arterial Thrombosiswhich Can Lead To Heart Attackacute Limb Ischemia And Strokea Phase Ii Clinical Trial In 160 Patients With Stroke Or Transient Ischaemic Attacktiahas Been Completedit Showed Beneficial Effects In Patients Treated With 120 Milligramsmgof Revacept Another Phase Ii Clinical Trial Investigated Revacept In 332 Patients With Stable Coronary Artery Diseaseisar Plasterhas Been Completedthis Study Conducted By The German Centre For Cardiovascular Researchdzhkconfirmed The Very Good Tolerability Of Revaceptoverallrevacept Did Not Lead To Increased Bleeding Despite Of Its Additional Platelet Aggregation Inhibition On Top Of Conventional Standard Therapyit Decreased Ischemic Strokes In Nmr And Improved The Net Clinical Benefit Of Mace And Bleeding Recentlythe Fda Has Approved The Preclinical And Clinical Development And The Further Phase 3 Protocol Until Market Approval Antibody Therapeuticin Collaboration With Morphosys An Anti Gpvi Fab Antibody Has Been Discoveredthe Candidate Is Currently In Preclinical Evaluation For The Treatment Of Acute Coronary Syndrome And Stroke Imprinthttps Www Advancecor De Imprint Privacy Policyhttps Www Advancecor De Privacy Policy